Sex, Gender, and Cardiovascular Disease in Chronic Kidney Disease

U.S. Renal Data System: USRDS annual report 2020. Accessed November 16, 2021. https://adr.usrds.org

Jankowski J Floege J Fliser D Böhm M Marx N.

Cardiovascular disease in chronic kidney disease.

Circulation. 143: 1157-1172

The clinical epidemiology of cardiovascular diseases in chronic kidney disease: cardiovascular disease in chronic renal failure: pathophysiologic aspects.

Semin Dial. 16: 85-94Levey AS Beto JA Coronado BE et al.

Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease.

Am J Kidney Dis. 32: 853-906

Cardiovascular complications in chronic kidney disease.

Am J Kidney Dis. 41: 11-17Perkovic V Jardine MJ Neal B et al.

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.

N Engl J Med. 380: 2295-2306Heerspink HJL Stefánsson BV Correa-Rotter R et al.

Dapagliflozin in patients with chronic kidney disease.

N Engl J Med. 383: 1436-1446Bakris GL Agarwal R Anker SD et al.

Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes.

N Engl J Med. 383: 2219-2229

Health Canada. Health portfolio sex and gender-based analysis policy. 2017. Accessed February 11, 2022.https://www.canada.ca/en/health-canada/corporate/transparency/corporate-management-reporting/heath-portfolio-sex-gender-based-analysis-policy.html

Cardiovascular disease and the female disadvantage.

Int J Environ Res Public Health. 16: E1165

Do sex and gender matter in kidney and cardiovascular disease?.

Am J Kidney Dis. 78: 177-179Pelletier R Khan NA Cox J et al.

Sex versus gender-related characteristics: which predicts outcome after acute coronary syndrome in the young?.

J Am Coll Cardiol. 67: 127-135O'Neil A Scovelle AJ Milner AJ Kavanagh A.

Gender/sex as a social determinant of cardiovascular risk.

Circulation. 137: 854-864Carrero JJ Hecking M Chesnaye NC Jager KJ.

Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease.

Nat Rev Nephrol. 14: 151-164Seng JJB Tan JY Yeam CT Htay H Foo WYM.

Factors affecting medication adherence among pre-dialysis chronic kidney disease patients: a systematic review and meta-analysis of literature.

Int Urol Nephrol. 52: 903-916Mosca L Barrett-Connor E Wenger NK.

Sex/gender differences in cardiovascular disease prevention what a difference a decade makes.

Circulation. 124: 2145-2154Peters SAE Muntner P Woodward M.

Sex differences in the prevalence of, and trends in, cardiovascular risk factors, treatment, and control in the United States, 2001 to 2016.

Circulation. 139: 1025-1035Birkeland KI Bodegard J Norhammar A et al.

How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study.

Diabetes Obes Metab. 21: 968-974Zhao M Woodward M Vaartjes I et al.

Sex differences in cardiovascular medication prescription in primary care: a systematic review and meta-analysis.

J Am Heart Assoc. 9e014742Shaw C Nitsch D Steenkamp R et al.

Inpatient coronary angiography and revascularisation following non-ST-elevation acute coronary syndrome in patients with renal impairment: a cohort study using the Myocardial Ischaemia National Audit Project.

PLoS One. 9: e99925Weiner DE Tighiouart H Elsayed EF et al.

The Framingham Predictive Instrument in chronic kidney disease.

J Am Coll Cardiol. 50: 217-224

Sex differences in coronary heart disease.

Circulation. 95: 252-264El Khoudary SR Aggarwal B Beckie TM et al.

Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association.

Circulation. 142: e506-e532

Sex hormones in women with kidney disease.

Nephrol Dial Transplant. 31: 1787-1795Kattah AG Smith CY Rocca LG Grossardt BR Garovic VD Rocca WA.

CKD in patients with bilateral oophorectomy.

Clin J Am Soc Nephrol. 13: 1649-1658Gallagher PE Li P Lenhart JR Chappell MC Brosnihan KB.

Estrogen regulation of angiotensin-converting enzyme mRNA.

Hypertension. 33: 323-328Dubey RK Oparil S Imthurn B Jackson EK.

Sex hormones and hypertension.

Cardiovasc Res. 53: 688-708Ramesh S James MT Holroyd-Leduc JM et al.

Estradiol and mortality in women with end-stage kidney disease.

Nephrol Dial Transplant. 35: 1965-1972Dousdampanis P Trigka K Fourtounas C Bargman JM.

Role of testosterone in the pathogenesis, progression, prognosis and comorbidity of men with chronic kidney disease.

Ther Apher Dial. 18: 220-230Carrero JJ Qureshi AR Parini P et al.

Low serum testosterone increases mortality risk among male dialysis patients.

J Am Soc Nephrol. 20: 613-620Sarnak MJ Amann K Bangalore S et al.

Chronic kidney disease and coronary artery disease.

J Am Coll Cardiol. 74: 1823-1838Go AS Chertow GM Fan D McCulloch CE Hsu C.

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

N Engl J Med. 351: 1296-1305

Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. 2010. Accessed November 21, 2021. https://www.nejm.org/doi/10.1056/NEJM197403282901301

Sarnak MJ Amann K Bangalore S et al.

Chronic kidney disease and coronary artery disease: JACC state-of-the-art review.

J Am Coll Cardiol. 74: 1823-1838Tamis-Holland JE Jneid H Reynolds HR et al.

Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease: a scientific statement from the American Heart Association.

Circulation. 139: e891-e908Zalewska-Adamiec M Malyszko J Grodzka E Kuzma L Dobrzycki S Bachorzewska-Gajewska H.

The outcome of patients with myocardial infarction with non-obstructive coronary arteries (MINOCA) and impaired kidney function: a 3-year observational study.

Int Urol Nephrol. 53: 2557-2566Engelbertz C Pinnschmidt HO Freisinger E et al.

Sex-specific differences and long-term outcome of patients with coronary artery disease and chronic kidney disease: the Coronary Artery Disease and Renal Failure (CAD-REF) Registry.

Clin Res Cardiol. 110: 1625-1636Zhang Q-L Rothenbacher D.

Prevalence of chronic kidney disease in population-based studies: systematic review.

BMC Public Health. 8: 117Virani SS Alonso A Aparicio HJ et al.

Heart disease and stroke statistics—2021 update.

Circulation. 143: e254-e743Muntner P He J Astor BC Folsom AR Coresh J.

Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities Study.

J Am Soc Nephrol. 16: 529-538Jung C-Y Heo GY Park JT et al.

Sex disparities and adverse cardiovascular and kidney outcomes in patients with chronic kidney disease: results from the KNOW-CKD.

Clin Res Cardiol. 110: 1116-1127Toth-Manikowski SM Yang W Appel L et al.

Sex differences in cardiovascular outcomes in CKD: findings from the CRIC study.

Am J Kidney Dis. 78: 200-209.e1

Coronary artery disease in chronic kidney disease: highlights from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Kidney Int. 97: 642-644Di Lullo L House A Gorini A Santoboni A Russo D Ronco C.

Chronic kidney disease and cardiovascular complications.

Heart Fail Rev. 20: 259-272House AA Wanner C Sarnak MJ et al.

Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Kidney Int. 95: 1304-1317Lullo LD Gorini A Russo D Santoboni A Ronco C.

Left ventricular hypertrophy in chronic kidney disease patients: from pathophysiology to treatment.

Cardiorenal Med. 5: 254-266Glassock RJ Pecoits-Filho R Barberato SH.

Left ventricular mass in chronic kidney disease and ESRD.

Clin J Am Soc Nephrol. 4: S79-S91

The clinical epidemiology of cardiovascular diseases in chronic kidney disease: clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis.

Semin Dial. 16: 101-105Löfman I Szummer K Dahlström U Jernberg T Lund LH.

Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction.

Eur J Heart Fail. 19: 1606-1614Gori M Senni M Gupta DK et al.

Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction.

Eur Heart J. 35: 3442-3451Damman K Valente MAE Voors AA O'Connor CM van Veldhuisen DJ Hillege HL

Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis.

Eur Heart J. 35: 455-469Ehdaie A Cingolani E Shehata M Wang X Curtis AB Chugh SS.

Sex differences in cardiac arrhythmias.

Circ Arrhythm Electrophysiol. 11 ()Tadros R Ton A-T Fiset C Nattel S.

Sex differences in cardiac electrophysiology and clinical arrhythmias: epidemiology, therapeutics, and mechanisms.

Can J Cardiol. 30: 783-792Ruff CT Giugliano RP Braunwald E et al.

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.

Lancet. 383: 955-962Humphries KH Kerr CR Connolly SJ et al.

New-onset atrial fibrillation.

Circulation. 103: 2365-2370Lip GYH Rushton-Smith SK Goldhaber SZ et al.

Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation?.

Circ Cardiovasc Qual Outcomes. 8: S12-S20Linde C Bongiorni MG Birgersdotter-Green U et al.

Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society.

Europace. 20 ()Bonato FOB Lemos MM Cassiolato JL Canziani MEF.

Prevalence of ventricular arrhythmia and its associated factors in nondialyzed chronic kidney disease patients.

PLoS One. 8 ()Bansal N Fan D Hsu C Ordonez JD Marcus GM Go AS.

Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease.

Circulation. 127: 569-574McManus DD Saczynski JS Ward JA et al.

The relationship between atrial fibrillation and chronic kidney disease : epidemiologic and pathophysiologic considerations for a dual epidemic.

J Atr Fibrillation. 5: 442Soliman EZ Prineas RJ Go AS et al.

Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC).

Am Heart J. 159: 1102-1107Baber U Howard VJ Halperin JL et al.

Association of chronic kidney disease with atrial fibrillation among adults in the United States.

Circ Arrhythm Electrophysiol. 4: 26-32

Management of traditional cardiovascular risk factors in CKD: what are the data?.

Am J Kidney Dis. 72: 728-744Shajahan S Amin J Phillips JK Hildreth CM.

Relationship between sex and cardiovascular mortality in chronic kidney disease: a systematic review and meta-analysis.

PLoS One. 16 ()Swartling O Rydell H Stendahl M Segelmark M Lagerros YT Evans M.

CKD progression and mortality among men and women: a nationwide study in Sweden.

Am J Kidney Dis. 78: 190-199.e1Meisinger C Döring A Löwel H Study Group KORA

Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population.

Eur Heart J. 27: 1245-1250Navaneethan SD Schold JD Walther CP et al.

HDL-cholesterol and causes of death in chronic kidney disease.

J Clin Lipidol. 12: 1061-1071.e7Chen S-C Teh M Huang J-C et al.

Increased aortic arch calcification and cardiomegaly is associated with rapid renal progression and increased cardiovascular mortality in chronic kidney disease.

Sci Rep. 9: 5354Lee W-H Hsu P-C Chu C-Y et al.

Upstroke time as a novel predictor of mortality in patients with chronic kidney disease.

Diagnostics (Basel). 10: 422Şimşek MA Değertekin M Türer Cabbar A et al.

NT-proBNP level in stage 3-4 chronic kidney disease and mortality in long-term follow-up: HAPPY study subgroup analysis.

Turk Kardiyol Dern Ars. 48: 454-460

Gestational Hypertension and Preeclampsia. Accessed November 30, 2021.https://www.acog.org/en/clinical/clinical-guidance/practice-bulletin/articles/2020/06/gestational-hypertension-and-preeclampsia

Wiles K Chappell LC Lightstone L Bramham K.

Updates in diagnosis and management of preeclampsia in women with CKD.

Clin J Am Soc Nephrol. 15: 1371-1380Garovic VD White W Vaughan L et al.

Incidence and long-term outcomes of hypertensive disorders of pregnancy.

J Am Coll Cardiol. 75: 2323-2334Honigberg MC Zekavat SM Aragam K et al.

Long-term cardiovascular risk in women with hypertension during pregnancy.

J Am Coll Cardiol. 74: 2743-2754Bellamy L Casas J-P Hingorani AD Williams DJ.

Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis.

BMJ. 335: 974

Kattah AG, Garovic VD. Chapter 9 - preeclampsia: cardiovascular and renal risks during and after pregnancy. In: LaMarca B, Alexander BT, eds. Sex Differences in Cardiovascular Physiology and Pathophysiology. Academic Press; 2019:137-147. Accessed December 3, 2021. https://www.sciencedirect.com/science/article/pii/B9780128131978000099

Stillman IE Karumanchi SA.

The glomerular injury of preeclampsia.

J Am Soc Nephrol. 18: 2281-2284Ferreira RC Fragoso MBT dos Santos Tenório MC et al.

Pre-eclampsia is associated with later kidney chronic disease and end-stage renal disease: systematic review and meta-analysis of observational studies.

Pregnancy Hypertens. 22: 71-85Piccoli GB Alrukhaimi M Liu Z-H et al.

Women and kidney diseases: questions unanswered and answers unquestioned.

Kidney Int Rep. 3: 225-235Garg AX Nevis IF McArthur E et al.

Gestational hypertension and preeclampsia in living kidney donors.

N Engl J Med. 372: 124-133Mjøen G Hallan S Hartmann A et al.

Long-term risks for kidney donors.

Kidney Int. 86: 162-167Garg AX Meirambayeva A Huang A et al.

Cardiovascular disease in kidney donors: matched cohort study.

BMJ. 344 ()Zinman B Wanner C Lachin JM et al.

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.

N Engl J Med. 373: 2117-2228Wanner C Inzucchi SE Lachin JM et al.

Empagliflozin and progression of kidney disease in type 2 diabetes.

N Engl J Med. 375: 323-334Zinman B Inzucchi SE Wanner C et al.

Empagliflozin in women with type 2 diabetes and cardiovascular disease – an analysis of EMPA-REG OUTCOME®.

Diabetologia. 61: 1522-1527

Gender differences in coronary heart disease.

Neth Heart J. 18: 598-602Johansson I Dahlström U Edner M Näsman P Rydén L Norhammar A.

Risk factors, treatment and prognosis in men and women with heart failure with and without diabetes.

Heart. 101: 1139-1148Neal B Perkovic V Mahaffey KW et al.

Canagliflozin and cardiovascular and renal events in type 2 diabetes.

N Engl J Med. 377: 644-657Perkovic V de Zeeuw D Mahaffey KW et al.

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.

Lancet Diabetes Endocrinol. 6: 691-704Yi TW Smyth B Kang A et al.

129-LB: kidney and cardiovascular effects of canagliflozin according to age and sex in the CREDENCE trial.

Diabetes. 70 ()Pitt B Filippatos G Agarwal R et al.

Cardiovascular events with finerenone in kidney disease and type 2 diabetes.

N Engl J Med. ()Tamargo J Rosano G Walther T et al.

Gender differences in the effects of cardiovascular drugs.

Eur Heart J Cardiovasc Pharmacother. 3: 163-182

Sex differences in pharmacokinetics and pharmacodynamics.

Clin Pharmacokinet. 48: 143-157Clemens KK Woodward M Neal B Zinman B.

Sex disparities in cardiovascular outcome trials of populations with diabetes: a systematic review and meta-analysis.

Diabetes Care. 43: 1157-1163

留言 (0)

沒有登入
gif